Skip to content
Back to announcement

20240430_SCPI_Laporan Informasi dan Fakta Material_31631948.pdf

Financial statement Text extracted SCPI

Source file signed link, expires in 15 minutes

This browser can't display the PDF inline. Open it in a new tab.

Extracted text 4

Page 1
Go To English Page

 Nomor Surat                       043/FIN/IV/2024

 Nama Perusahaan                   PT Organon Pharma Indonesia Tbk

 Kode Emiten                       SCPI

 Lampiran                          4
                                   Penyampaian Laporan Keuangan
 Perihal



Tahun Fiskal                           :   2024

Tahun Buku                             :   DEC

Jenis Periode                          :   Kuartal I / First Quarter


Dengan ini kami untuk dan atas nama perusahaan menyampaikan laporan keuangan, sebagai berikut:



Nama Emiten                            :   PT Organon Pharma Indonesia Tbk

Bidang Usaha                           :   Industri Farmasi


Nilai Ekuitas                          :   887.962.191

Nilai Pendapatan Periode Sebelumnya :      581.070.038

Nilai Pendapatan                       :   692.835.232

Selisih dengan Nilai Pendapatan            111.765.194
                                       :
Periode Sebelumnya

Kurs                                   :   Rupiah / IDR

Rate                                   :

Jenis Laporan atas Laporan Keuangan :      Tidak Diaudit / Unaudit


Informasi Lain

Sehubungan dengan adanya kendala penyampaian Laporan Keuangan Interim yang Tidak Diaudit - Kuartal I 2024,
berbasis XBRL, maka dengan ini kami secara paralel menyampaikan Laporan Keuangan Interim Kuartal I 2024 yang
Tidak Diaudit dengan menggunakan form E019 sesuai dengan himbauan dari IDX yang disampaikan melalui email pada
tanggal 29 April 2024. Sebelumnya kami sudah melakukan pelaporan XBRL dengan status akhir "on progress final
submit".
Terima kasih.

 Demikian untuk diketahui.


 Hormat Kami,
 PT Organon Pharma Indonesia Tbk




 Arie Noviandari

 approver dua




 PT Organon Pharma Indonesia Tbk
 Sinarmas MSIG Tower, Lantai 37, unit 102 & 106, Jalan Jenderal Sudirman Kaveling
Page 2
Telepon : 085951102178, Fax : 021-31107009, https://www.organon.com/indonesia/



Nama Pengirim                    Arie Noviandari

Jabatan                          approver dua
Tanggal dan Waktu                30-04-2024 14:47

Lampiran                         1. Penjelasan Perubahan Liabilitas OPI Q1 2024.pdf


                                 2. Surat Pengantar OJK OPI Q1 2024.pdf


                                 3. Directors Statement OPI Q1 2024.pdf


                                 4. 2024_OPI_Q1_FS OPI 31 March 2024_FINAL.pdf


 Dokumen ini merupakan dokumen resmi PT Organon Pharma Indonesia Tbk yang tidak memerlukan tanda tangan
     karena dihasilkan secara elektronik oleh sistem pelaporan elektronik. PT Organon Pharma Indonesia Tbk
                    bertanggung jawab penuh atas informasi yang tertera didalam dokumen ini.
Page 3
Go To Indonesian Page

 Letter / Announcement No.           043/FIN/IV/2024

 Issuer Name                         PT Organon Pharma Indonesia Tbk

 Issuer Code                         SCPI

 Attachment                          4

 Subject                             Submission of Financial Report


Fiscal Year                              :   2024

End of Year                              :   DEC

Period Type                              :   Kuartal I / First Quarter


The company hereby announce the Submission of Financial Report as follows:



Issuer Name                              :   PT Organon Pharma Indonesia Tbk

Business Fields                          :   Industri Farmasi


Equity Value                             :   887.962.191

Previous Period Revenue                  :   581.070.038

Revenue                                  :   692.835.232

Difference with Previous Period              111.765.194
                                         :
Revenue

Currency                                 :   Rupiah / IDR

Rate                                     :

Types of Reports on Financial            :   Tidak Diaudit / Unaudit

Other Information

Due to the difficulties in submitting the XBRL-based of Unaudited Interim Financial Statements First Quarter 2024,
we are hereby parallelly submitting Unaudited Interim Financial Statements First Quarter 2024 using form E019, in
accordance with the advice from the IDX which was conveyed via email on 29 April 2024. Please be informed we
previously had submitted the XBRL reporting with the last status "on progress final submit.
Thank you.

Thus to be informed accordingly.


Respectfully,
PT Organon Pharma Indonesia Tbk




Arie Noviandari

approver dua




PT Organon Pharma Indonesia Tbk
Sinarmas MSIG Tower, Lantai 37, unit 102 & 106, Jalan Jenderal Sudirman Kaveling
Phone : 085951102178, Fax : 021-31107009, https://www.organon.com/indonesia/
Page 4
Sender Name                        Arie Noviandari

Function                           approver dua

Date and Time                      30-04-2024 14:47

Attachment                        1. Penjelasan Perubahan Liabilitas OPI Q1 2024.pdf


                                  2. Surat Pengantar OJK OPI Q1 2024.pdf


                                  3. Directors Statement OPI Q1 2024.pdf


                                  4. 2024_OPI_Q1_FS OPI 31 March 2024_FINAL.pdf


   This is an official document of PT Organon Pharma Indonesia Tbk that does not require a signature as it was
 generated electronically by the electronic reporting system. PT Organon Pharma Indonesia Tbk is fully responsible
                                  for the information contained within this document.

File

File Open PDF
Source IDX
Size0.01 MB
Published30 Apr 2024
Pages4
Characters5,416
Text sourceEmbedded text layer
OCR confidence—

Names mentioned 2 people and organisations named in the text · linked when the evidence is strong

linked org Organon Pharma Indonesia Tbk · Nama Perusahaan p.1 ×38
linked person Arie Noviandari · approver dua p.1 ×5

Extraction attempts how the parser did, and what it refused

Nothing structured was extracted from this document — the attempts below say why.

No extraction attempted yet.

↑↓ select ↵ open ⇧↵ see every result